Yazhou Yao

Jiangtan Road
Baoji, 721008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Correction: Single and combined use of the platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in hemorrhagic fever with renal syndrome.

Correction: Single and combined use of the platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in hemorrhagic fever with renal syndrome.

Journal: Frontiers in cellular and infection microbiology

Published: June 24, 2026

Single and combined use of the platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in hemorrhagic fever with renal syndrome.

Single and combined use of the platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in hemorrhagic fever with renal syndrome.

Journal: Frontiers in cellular and infection microbiology

Published: November 12, 2025

Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.

Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.

Journal: Research and practice in thrombosis and haemostasis

Published: July 03, 2025

Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.

Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.

Journal: Annals of hematology

Published: April 17, 2024

Parainfluenza virus 5 is a next-generation vaccine vector for human infectious pathogens.

Parainfluenza virus 5 is a next-generation vaccine vector for human infectious pathogens.

Journal: Journal of medical virology

Published: November 03, 2022

Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.

Aberrant expression of GOLM1 protects ALK+ anaplastic large cell lymphoma from apoptosis by enhancing BCL-XL stability.

Journal: Blood advances

Published: June 28, 2022

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 09, 2021

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

Journal: Journal of hematology & oncology

Published: December 16, 2020

Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.

Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.

Journal: Trials

Published: February 01, 2019

Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.

Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: November 26, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026